Cargando…

In Vitro Activity of Ibrexafungerp against a Collection of Clinical Isolates of Aspergillus, Including Cryptic Species and Cyp51A Mutants, Using EUCAST and CLSI Methodologies

Ibrexafungerp is a new orally-available 1,3-β-D-glucan synthesis inhibitor in clinical development. Its in vitro activity and that of amphotericin B, voriconazole, and micafungin were evaluated against a collection of 168 clinical isolates of Aspergillus spp., including azole–susceptible and azole–r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rivero-Menendez, Olga, Soto-Debran, Juan Carlos, Cuenca-Estrella, Manuel, Alastruey-Izquierdo, Ana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003840/ https://www.ncbi.nlm.nih.gov/pubmed/33804780 http://dx.doi.org/10.3390/jof7030232

Ejemplares similares

Point Mutations in the 14-α Sterol Demethylase Cyp51A or Cyp51C Could Contribute to Azole Resistance in Aspergillus flavus
por: Lucio, Jose, et al.
Publicado: (2020)

Time to switch from CLSI to EUCAST? A Southeast Asian perspective
por: Cusack, T.P., et al.
Publicado: (2019)

Triazole Resistance in Aspergillus spp.: A Worldwide Problem?
por: Rivero-Menendez, Olga, et al.
Publicado: (2016)

EUCAST Ibrexafungerp MICs and Wild-Type Upper Limits for Contemporary Danish Yeast Isolates
por: Jørgensen, Karin M., et al.
Publicado: (2022)

Impact of CLSI and EUCAST breakpoint discrepancies on reporting of antimicrobial susceptibility and AMR surveillance
por: Cusack, T.P., et al.
Publicado: (2019)

Ceftaroline Susceptibility among Isolates of MRSA: A Comparison of EUCAST and CLSI Breakpoints
por: Sachu, Arun
Publicado: (2023)

Molecular Identification and Antifungal Susceptibility Patterns of Clinical Dermatophytes Following CLSI and EUCAST Guidelines
por: Dabas, Yubhisha, et al.
Publicado: (2017)

Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates
por: Pfaller, Michael A., et al.
Publicado: (2016)

Change of Antibiotic Susceptibility Testing Guidelines from CLSI to EUCAST: Influence on Cumulative Hospital Antibiograms
por: Wolfensberger, Aline, et al.
Publicado: (2013)

1269. Differences in Interpretative Breakpoints Between CLSI, FDA and EUCAST Impact Reporting of Susceptibility and Resistance to Cefiderocol
por: Yamano, Yoshinori, et al.
Publicado: (2020)

In Vitro Fluconazole and Voriconazole Susceptibilities of Candida Bloodstream Isolates in Korea: Use of the CLSI and EUCAST Epidemiological Cutoff Values
por: Jang, Min Joong, et al.
Publicado: (2013)

Prevalence of susceptibility patterns of opportunistic bacteria in line with CLSI or EUCAST among Haemophilus parainfluenzae isolated from respiratory microbiota
por: Kosikowska, Urszula, et al.
Publicado: (2020)

Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections
por: Angulo, David A., et al.
Publicado: (2022)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Haemophilus influenzae blood-stream infection and third-generation cephalosporin susceptibility testing: a comparative case study using EUCAST and CLSI guidelines
por: Merlino, John, et al.
Publicado: (2023)

Spectrophotometric detection of azole-resistant Aspergillus fumigatus with the EUCAST broth microdilution method: is it time for automated MIC reading of EUCAST antifungal susceptibility testing of Aspergillus species?
por: Meletiadis, Joseph, et al.
Publicado: (2022)

Interpretation of Antimicrobial Susceptibility Testing Using European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Clinical and Laboratory Standards Institute (CLSI) Breakpoints: Analysis of Agreement
por: Gaur, Priyanka, et al.
Publicado: (2023)

CLSI announces availability of new CLSI microbiology documents
Publicado: (2007)

1597. Evaluation of Ceftaroline Resistance (CPT-R) in Chile Across Time and a Comparison of CLSI vs. EUCAST Breakpoints in Methicillin-Resistant Staphylococcus aureus (MRSA)
por: Khan, Ayesha, et al.
Publicado: (2019)

Differentiation of Aspergillus flavus from Aspergillus oryzae Targeting the cyp51A Gene
por: Nargesi, Sanaz, et al.
Publicado: (2021)

Updated EUCAST Clinical Breakpoints against Aspergillus, Implications for the Clinical Microbiology Laboratory
por: Guinea, Jesús
Publicado: (2020)

Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp
por: Grant, Leah M., et al.
Publicado: (2022)

Study of Azole - Resistant and Cyp51a Gene in Aspergillus Fumigatus
por: Zarrin, Majid, et al.
Publicado: (2018)

Genomic and Phenotypic Heterogeneity of Clinical Isolates of the Human Pathogens Aspergillus fumigatus, Aspergillus lentulus, and Aspergillus fumigatiaffinis
por: dos Santos, Renato A. C., et al.
Publicado: (2020)

A Cyp51B Mutation Contributes to Azole Resistance in Aspergillus fumigatus
por: Gonzalez-Jimenez, Irene, et al.
Publicado: (2020)

Instruction videos from EUCAST
Publicado: (2020)

The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
por: Hoenigl, Martin, et al.
Publicado: (2021)

Draft Genome Sequences of Four Aspergillus Section Fumigati Clinical Strains
por: dos Santos, Renato Augusto Corrêa, et al.
Publicado: (2020)

Itraconazole, Voriconazole, and Posaconazole CLSI MIC Distributions for Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates
por: Buil, Jochem B., et al.
Publicado: (2018)

Examining Signatures of Natural Selection in Antifungal Resistance Genes Across Aspergillus Fungi
por: dos Santos, Renato Augusto Corrêa, et al.
Publicado: (2021)

A conceptual framework for nomenclatural stability and validity of medically important fungi: a proposed global consensus guideline for fungal name changes supported by ABP, ASM, CLSI, ECMM, ESCMID-EFISG, EUCAST-AFST, FDLC, IDSA, ISHAM, MMSA, and MSGERC
por: de Hoog, Sybren, et al.
Publicado: (2023)

The Feasibility of Ibrexafungerp for the Treatment of Fungal Infections in Patients with Hematological Malignancies
por: Daraskevicius, Justinas, et al.
Publicado: (2022)

Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy
por: Phillips, Nancy A, et al.
Publicado: (2023)

Deciphering Aspergillus fumigatus cyp51A-mediated triazole resistance by pyrosequencing of respiratory specimens
por: Novak-Frazer, Lilyann, et al.
Publicado: (2020)

Uncovering New Mutations Conferring Azole Resistance in the Aspergillus fumigatus cyp51A Gene
por: Chen, Peiying, et al.
Publicado: (2020)

Azole Resistance-Associated Regulatory Motifs within the Promoter of cyp51A in Aspergillus fumigatus
por: Kühbacher, Alexander, et al.
Publicado: (2022)

Re: In the name of common sense: EUCAST breakpoints and potential pitfalls. National dissemination of EUCAST guidelines is a shared responsibility
por: Kahlmeter, Gunnar, et al.
Publicado: (2020)

Azole Resistance and cyp51A Mutation of Aspergillus fumigatus in a Tertiary Referral Hospital in Taiwan
por: Hsu, Tsun-Hao, et al.
Publicado: (2022)

1251. Prevention of Pneumocystis Pneumonia by Ibrexafungerp in a Murine Prophylaxis Model
por: Borroto-Esoda, Katyna, et al.
Publicado: (2020)

Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor
por: Jallow, Sabelle, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e80dtop90qiqdm9i7kv7b8gfut